Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA2 | O43464 | 8/20 | 0.54 |
| ▸ | HTRA1 | Q92743 | 8/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932614 | 0.94 | HTRA2 (0.52) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL20047392 | 0.93 | FOLH1 (0.51) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL20235710 | 0.93 | HTRA2 (0.49) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL14932664 | 0.89 | HTRA2 (0.58) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL19967086 | 0.87 | FOLH1 (0.50) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL14932612 | 0.86 | HTRA2 (0.67) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL14932598 | 0.83 | HTRA2 (0.62) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL13833492 | 0.83 | HTRA2 (0.38) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL21385766 | 0.81 | HTRA2 (0.39) | HTRA2HTRA1FOLH1ALBWDR5 | |
| SCHEMBL16234096 | 0.80 | HTRA2 (0.65) | HTRA2HTRA1FOLH1ALBWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11377423-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAc Therapeutics, Inc. | 2021-06-17 | — | — | US | disclosed |
| EP-2877444-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10626438-B2 | Fluorescent substrates for determining lysine modifying enzyme activity | THE BROAD INSTITUTE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626438-B2 | Fluorescent substrates for determining lysine modifying enzyme activity | THE BROAD INSTITUTE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | KDAC THERAPEUTICS INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180155760-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | BROAD INST INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9447030-B2 | Inhibitors of histone deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9365498-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150191427-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140335550-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | THE BROAD INSTITUTE, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335550-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | THE BROAD INSTITUTE, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| WO-2014018979-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013067391-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | THE BROAD INSTITUTE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080800-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HTRA2 2080/4885HTRA1 558/4885FOLH1 3742/4885 |
| US-20210177781-A9 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HTRA2 3910/4885HTRA1 3017/4885FOLH1 1441/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HTRA2 2080/4885HTRA1 558/4885FOLH1 3742/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HTRA2 2080/4885HTRA1 558/4885FOLH1 3742/4885 |
| US-20190216754-A1 | COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, HDAC7 | HTRA2 3910/4885HTRA1 3017/4885FOLH1 1441/4885 |
| US-20180155760-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | KDM1A, MAN2B1, KDM3A | HTRA2 3856/4885HTRA1 1400/4885FOLH1 814/4885 |
| US-20150191427-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC5 | HTRA2 3718/4885HTRA1 2398/4885FOLH1 3543/4885 |
| US-20160251351-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | HTRA2 1825/4885HTRA1 378/4885FOLH1 3931/4885 |
| US-11377423-B2 | Inhibitors of histone deacetylase | HDAC3, HDAC1, HDAC11 | HTRA2 3610/4885HTRA1 2119/4885FOLH1 3741/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HTRA2 2080/4885HTRA1 558/4885FOLH1 3742/4885 |
| US-10626438-B2 | Fluorescent substrates for determining lysine modifying enzyme activity | KDM1A, MAN2B1, KDM3A | HTRA2 3856/4885HTRA1 1400/4885FOLH1 814/4885 |
| US-20140335550-A1 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY | MAN2B1, KDM1A, KDM3A | HTRA2 3894/4885HTRA1 1291/4885FOLH1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.